Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Molecular Advances in Bone Metabolism and Disorders
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Advances in Bone Metabolism and Disorders

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1678

Special Issue Editor

Dr. Hyuk-Sang Jung

E-Mail Website
Guest Editor
Department of Anatomy, College of Korean Medicine, Seoul 02447, Republic of Korea
Interests: bone metabolism; molecular mechanisms; molecular biology of bone remodeling; bone aging; bone disease; osteoporosis; drug development; osteoclast; osteoblast; osteocyte

Special Issue Information

Dear Colleagues,

Understanding the intricate molecular mechanisms underlying bone metabolism is essential for unraveling the complexities of bone-related diseases and developing targeted therapeutic interventions. By investigating the molecular pathways involved in bone homeostasis, researchers can uncover novel biomarkers, identify therapeutic targets, and devise personalized treatment strategies. Moreover, elucidating the molecular basis of bone disorders contributes to the broader field of regenerative medicine and tissue engineering, paving the way for innovative approaches in bone regeneration and repair. Harnessing the power of molecular advances in this field not only expands our knowledge of bone biology but also has the potential to improve patient outcomes and quality of life for individuals affected by bone disorders.

This Special Issue aims to delve into cutting-edge molecular-level knowledge pertaining to advanced research and conditions related to bone biology. Together, we aim to gather leading experts from the field to drive forward new advancements. We eagerly invite you to share your research findings and insights in this Special Issue, welcoming contributions from various perspectives, including, but not limited to, bone metabolism, molecular biology, molecular mechanisms, and drug development for bone-related disorders. We look forward to your scholarly contributions, and if you intend to submit a research paper to our Special Issue, kindly ensure it is submitted within the specified deadline. We highly anticipate your active participation, contributing to the successful publication of our Special Issue.

Dr. Hyuk-Sang Jung
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bone metabolism
  • molecular mechanisms
  • molecular biology of bone remodeling
  • bone aging
  • bone disease
  • osteoporosis
  • drug development
  • osteoclast
  • osteoblast
  • osteocyte

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

21 pages, 2998 KiB  
Review
Links among Obesity, Type 2 Diabetes Mellitus, and Osteoporosis: Bone as a Target
by Monika Martiniakova, Roman Biro, Noemi Penzes, Anna Sarocka, Veronika Kovacova, Vladimira Mondockova and Radoslav Omelka
Int. J. Mol. Sci. 2024, 25(9), 4827; https://doi.org/10.3390/ijms25094827 - 28 Apr 2024
Viewed by 386
Abstract
Obesity, type 2 diabetes mellitus (T2DM) and osteoporosis are serious diseases with an ever-increasing incidence that quite often coexist, especially in the elderly. Individuals with obesity and T2DM have impaired bone quality and an elevated risk of fragility fractures, despite higher and/or unchanged [...] Read more.
Obesity, type 2 diabetes mellitus (T2DM) and osteoporosis are serious diseases with an ever-increasing incidence that quite often coexist, especially in the elderly. Individuals with obesity and T2DM have impaired bone quality and an elevated risk of fragility fractures, despite higher and/or unchanged bone mineral density (BMD). The effect of obesity on fracture risk is site-specific, with reduced risk for several fractures (e.g., hip, pelvis, and wrist) and increased risk for others (e.g., humerus, ankle, upper leg, elbow, vertebrae, and rib). Patients with T2DM have a greater risk of hip, upper leg, foot, humerus, and total fractures. A chronic pro-inflammatory state, increased risk of falls, secondary complications, and pharmacotherapy can contribute to the pathophysiology of aforementioned fractures. Bisphosphonates and denosumab significantly reduced the risk of vertebral fractures in patients with both obesity and T2DM. Teriparatide significantly lowered non-vertebral fracture risk in T2DM subjects. It is important to recognize elevated fracture risk and osteoporosis in obese and T2DM patients, as they are currently considered low risk and tend to be underdiagnosed and undertreated. The implementation of better diagnostic tools, including trabecular bone score, lumbar spine BMD/body mass index (BMI) ratio, and microRNAs to predict bone fragility, could improve fracture prevention in this patient group. Full article
(This article belongs to the Special Issue Molecular Advances in Bone Metabolism and Disorders)
22 pages, 1935 KiB  
Review
Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies
by Alessandra Di Paola, Maria Maddalena Marrapodi, Martina Di Martino, Giulia Giliberti, Giuseppe Di Feo, Deeksha Rana, Shakeel Ahmed, Maura Argenziano, Francesca Rossi and Domenico Roberti
Int. J. Mol. Sci. 2024, 25(5), 2902; https://doi.org/10.3390/ijms25052902 - 01 Mar 2024
Viewed by 861
Abstract
Hemoglobinopathies are monogenic disorders affecting hemoglobin synthesis. Thalassemia and sickle cell disease (SCD) are considered the two major hemoglobinopathies. Thalassemia is a genetic disorder and one of the major hemoglobinopathies determined by an impairment of globin chain production, which causes an alteration of [...] Read more.
Hemoglobinopathies are monogenic disorders affecting hemoglobin synthesis. Thalassemia and sickle cell disease (SCD) are considered the two major hemoglobinopathies. Thalassemia is a genetic disorder and one of the major hemoglobinopathies determined by an impairment of globin chain production, which causes an alteration of erythropoiesis, an improvement in hemolysis, and an alteration of iron homoeostasis. In SCD, the mutations are on the β-globin chain of hemoglobin which results in a substitution of glutamic acid by valine with consequent formation of Hemoglobin S (HbS). Several factors are involved in bone metabolism alteration in patients with hemoglobinopathies, among them hormonal deficiency, bone marrow hyperplasia, iron overload, inflammation, and increased bone turnover. Bone metabolism is the result of balance maintenance between bone deposition and bone resorption, by osteoblasts (OBs) and osteoclasts (OCs). An impairment of this balance is responsible for the onset of bone diseases, such as osteoporosis (OP). Therefore, here we will discuss the alteration of bone metabolism in patients with hemoglobinopathies and the possible therapeutic strategies to contain and/or counteract bone health impairment in these patients, taking into consideration not only the pharmacological treatments already used in the clinical armamentarium, but also the new possible therapeutic strategies. Full article
(This article belongs to the Special Issue Molecular Advances in Bone Metabolism and Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop